| 1 |
Mitochondrial transplantation as a novel treatment for sensorineural hearing loss |
| Others |
Hearing loss |
Sensorineural hearing loss (with mitochondrial defects) |
Candidate |
Paean Biotechnology Inc. |
RS-2023-00283926 |
|
| 2 |
A Phase 2b clinical study for iron.based T1.MRI contrast agent: Advancing towards Phase 3 |
| Others |
Lymphadenopathy |
Arthrography using magnetic resonance imaging (MRI) for shouler, hip, elbow, knee, wrist, and ankle |
Phase 2 |
Inventera Pharmaceuticals Inc. |
RS-2023-00282888 |
|
| 3 |
Pre-clinical studies of DMOAD candidate DRT-101 for Osteoarthritis |
| Others |
Degenerative arthritis |
bmp7 |
Preclinical |
Darnatein |
RS-2023-00258278 |
|
| 4 |
|
| Others |
Bronchopulmonary Dysplasia(BPD) |
Ago2 |
Lead |
Samsung Medical Center |
HN22C0414 |
|
| 5 |
Development of a highly stable and safe macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others |
MRI contrast agent |
Gd-ligand |
Candidate |
PharmGen Science, Inc. |
HN22C0196 |
|
| 6 |
Development of a HNP-2006 contrast agent with improved safety |
| Others |
MRI contrast agent |
Gd-ligand |
Phase 2 |
Hana Pharm Co., Ltd. |
HN21C1298 |
|
